Artivion, Inc. (NYSE:AORT) Receives $32.00 Consensus Price Target from Brokerages

Artivion, Inc. (NYSE:AORT - Get Free Report) has received a consensus recommendation of "Buy" from the seven analysts that are currently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $32.00.

A number of research analysts have recently issued reports on the company. Citizens Jmp raised Artivion to a "strong-buy" rating in a report on Tuesday, May 6th. Canaccord Genuity Group assumed coverage on Artivion in a report on Tuesday, June 17th. They set a "buy" rating and a $35.00 price target on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $32.00 price target on shares of Artivion in a report on Tuesday, May 6th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $33.00 price target on shares of Artivion in a report on Tuesday, May 6th.

Artivion Stock Up 1.8%

Artivion stock traded up $0.55 during mid-day trading on Thursday, hitting $31.17. The company had a trading volume of 543,052 shares, compared to its average volume of 336,700. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08. The stock's 50 day moving average price is $27.99 and its two-hundred day moving average price is $27.50. Artivion has a 12 month low of $21.97 and a 12 month high of $32.33. The company has a market capitalization of $1.33 billion, a PE ratio of -62.34 and a beta of 1.61.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). The business had revenue of $98.98 million for the quarter, compared to the consensus estimate of $94.81 million. Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. As a group, sell-side analysts anticipate that Artivion will post 0.37 earnings per share for the current fiscal year.

Insider Activity at Artivion

In related news, SVP Jean F. Holloway sold 9,926 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total transaction of $287,854.00. Following the completion of the sale, the senior vice president now owns 187,258 shares in the company, valued at approximately $5,430,482. This represents a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marshall S. Stanton sold 26,132 shares of the company's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $28.44, for a total value of $743,194.08. Following the sale, the senior vice president now owns 79,200 shares of the company's stock, valued at approximately $2,252,448. This trade represents a 24.81% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 72,954 shares of company stock worth $2,108,525. 8.10% of the stock is owned by insiders.

Institutional Trading of Artivion

Hedge funds have recently bought and sold shares of the company. Millennium Management LLC increased its position in Artivion by 25.1% during the fourth quarter. Millennium Management LLC now owns 165,482 shares of the company's stock valued at $4,731,000 after acquiring an additional 33,220 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in Artivion during the fourth quarter valued at $194,000. New York State Common Retirement Fund increased its position in Artivion by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 41,017 shares of the company's stock valued at $1,173,000 after acquiring an additional 1,000 shares during the last quarter. JPMorgan Chase & Co. increased its position in Artivion by 64.2% in the fourth quarter. JPMorgan Chase & Co. now owns 160,796 shares of the company's stock worth $4,597,000 after buying an additional 62,893 shares in the last quarter. Finally, Deutsche Bank AG increased its position in Artivion by 45.1% in the fourth quarter. Deutsche Bank AG now owns 36,982 shares of the company's stock worth $1,057,000 after buying an additional 11,501 shares in the last quarter. Hedge funds and other institutional investors own 86.37% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.